Company type | Société Anonyme |
---|---|
LSE: NCYT Euronext: ALNOV | |
Industry | Biotechnology |
Founded | 2006 |
Headquarters | Camberley, Surrey, United Kingdom |
Key people | David Allmond (CEO) |
Products | In vitro and molecular diagnostics |
Subsidiaries | |
Website | www.novacyt.com |
Novacyt Group (/ˈnoʊvəsaɪt/ NOH-və-syte) is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France.[1][2] The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide.[3] Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.[4]
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV.[5][6][7][8] The test was approved as eligible for procurement under the World Health Organization's (WHO) Emergency Use Listing process in April 2020,[9] meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response.[10] In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory.[11][12]